Methotrexate

證據等級: L5

預測適應症: 10 個

Methotrexate: From Antineoplastic/Antirheumatic Therapy to Pulmonary Blastoma

One-Sentence Summary

Methotrexate (DrugBank DB00563) is a long-established antifolate agent used broadly across oncology and autoimmune disease; specific original-indication records were not available in this evidence pack. The TxGNN model’s top-ranked prediction is Pulmonary Blastoma, but currently 0 clinical trials and 0 publications support this specific link — the prediction rests on the model score alone.

Quick Overview

Item	Content
Original Indication	Not available in regulatory records (no TFDA/market license data returned); methotrexate is broadly known as an antineoplastic/antirheumatic agent
Predicted New Indication	Pulmonary Blastoma
TxGNN Prediction Score	99.45%
Evidence Level	L5
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap, DG002). Based on generally known pharmacology, methotrexate belongs to the antifolate (dihydrofolate reductase inhibitor) class of antimetabolite chemotherapy agents, which broadly inhibits DNA/RNA synthesis in rapidly dividing cells.

Pulmonary blastoma is an extremely rare, aggressive pulmonary malignancy with mixed epithelial and mesenchymal components. In principle, an antimetabolite chemotherapy agent could have some theoretical activity against such a rapidly proliferating tumor, consistent with methotrexate’s general use in other malignancies. However, this rationale is purely mechanistic extrapolation — there is no direct or indirect clinical evidence (trial or literature) connecting methotrexate specifically to pulmonary blastoma in the data available here.

Notably, this is the highest-scoring candidate in the TxGNN output but also the one with the weakest evidentiary support among the 10 candidates in this evidence pack — other predicted indications for methotrexate (e.g., Hodgkin’s lymphoma, ranked #5) carry substantially more clinical trial and literature backing (see Conclusion below).

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Cytotoxicity

Methotrexate is a conventional cytotoxic agent (antimetabolite / folate antagonist class), consistent with its long-standing use in oncology.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (Antimetabolite, folate antagonist)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.

Note: TFDA label warnings/contraindications data is flagged as a Blocking data gap (DG001) — this prevents the candidate from entering the S1 safety pre-assessment stage.

Conclusion and Next Steps

Decision: Hold

Rationale: This prediction is supported only by a TxGNN model score (L5 evidence level) with no clinical trials or literature identified for methotrexate in pulmonary blastoma, and no TFDA safety data is currently available to support even a preliminary safety assessment.

To proceed, the following is needed:

TFDA label/insert data (warnings, contraindications) — currently a Blocking data gap
Confirmed mechanism of action data via DrugBank API — currently a High-severity data gap
Any preclinical or case-level evidence specific to pulmonary blastoma to move beyond L5
Consider reprioritizing evaluation toward the higher-evidence candidates in this same evidence pack — notably Hodgkin’s lymphoma (L2, decision stage S2, “Proceed with Guardrails”), which has direct historical trial evidence (e.g., VBM regimen) and substantially more supporting literature
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.